Trulance (plecanatide) is a 3 mg tablet taken once a day for chronic idiopathic constipation or irritable bowel syndrome with constipation, so its price is a price per tablet multiplied by 30 or 90. No retail cash price could be read on 17 November 2026: GoodRx redirected to a block page, and SingleCare and Drugs.com returned HTTP 403. Per this site's method, a refused page is excluded, never quoted from a search snippet.
What remains is four public datasets and one finding the price-comparison sites do not show: Trulance dropped out of Medicaid's national price survey and its rebate-program file at the same point in late 2025. What plecanatide is and how it works is on Peptide Lexicon's plecanatide entry; the costs of the other drug in its class are on our Linzess cost page.
The prices, side by side
| Benchmark | Per tablet | 30 tablets | Source and date |
|---|---|---|---|
| National average pharmacy acquisition cost | $18.05 | $541.63 | Medicaid NADAC, effective 17 Sep 2025 (last listing, file of 1 Oct 2025) |
| Medicare average spending, 2024 | $18.11 | $543 | CMS Part D Spending by Drug, 2024 (before rebates) |
| Medicare average per claim, 2025 | — | $843 per claim | CMS Quarterly Part D Spending by Drug, 2025 |
| Medicare average per claim, Q1 2026 | — | $913 per claim | Same, first quarter 2026 |
| Manufacturer savings card | — | as little as $25 per fill | trulance.com, read 17 Nov 2026 (commercial insurance only) |
The 30-tablet figures for NADAC and the 2024 Medicare row are our multiplication; CMS publishes per-unit spending and per-claim averages, and a Part D claim can cover 30 or 90 days, so per-claim figures are not a 30-day price.
What pharmacies paid, and when the survey stopped
NADAC is Medicaid's weekly survey of what retail pharmacies paid wholesalers. Its 2024 and 2025 files for Trulance 3 mg (NDC 65649-0003-30) read:
| NADAC effective date | Per tablet |
|---|---|
| 18 October 2023 | $17.22 |
| 1 January 2024 | $17.84 |
| 22 January 2025 | $17.84 |
| 8 March 2025 | $18.09 |
| 17 September 2025 | $18.05 |
| Files after 1 October 2025 | not listed |
Over two years the acquisition cost rose 4.9%. Then it stopped being reported: the last weekly file carrying Trulance is dated 1 October 2025, and the 2026 dataset, current to 11 November 2026, has no Trulance row and no plecanatide row of any kind. In the same files, Linzess is priced every week.
Medicaid: a quarter after which Trulance is missing
CMS publishes a quarterly file of every drug product a manufacturer has enrolled in the Medicaid Drug Rebate Program, the arrangement under which state Medicaid programmes cover a company's drugs in return for rebates. On 17 November 2026 that file listed Trulance in every quarter we read, through the third quarter of 2025, and in none of the four quarters from the fourth quarter of 2025 to the third quarter of 2026, the latest the file holds. Linzess is listed in every one of those quarters.
Two other public records sit beside this. NADAC stopped surveying Trulance at the start of October 2025, the same point. And the Trulance website carries a "Medicaid Changes" banner linking to Bausch Health's patient-assistance site, which states: "If your plan stopped covering your Bausch Health Medication(s), you may be eligible to receive it for free." We found no public statement from Bausch Health or Salix giving the reason or the date, so this page reports what the files show and does not infer a cause. A Medicaid enrollee's own state plan is the source for its current coverage.
Medicare: what it spends, and why there is no negotiated price
| Year | Part D spending | Claims | People | Per claim | Per person |
|---|---|---|---|---|---|
| 2022 | $87.6 million | 120,128 | 35,495 | $729 | $2,468 |
| 2023 | $119.3 million | 147,995 | 41,836 | $806 | $2,851 |
| 2024 | $123.2 million | 155,096 | 44,622 | $795 | $2,762 |
| 2025 | $128.9 million | 152,886 | 42,704 | $843 | $3,018 |
| Q1 2026 | $30.1 million | 32,948 | 20,857 | $913 | — |
All figures are CMS's, before manufacturer rebates, which CMS does not publish per drug. Spending per claim rose 6% from 2024 to 2025 and a further 8% in the first quarter of 2026 against the 2025 average. For scale: Medicare spent $1.98 billion on Linzess in 2024, about 16 times its Trulance spending.
Trulance is not on CMS's lists of drugs selected for negotiation for 2026, 2027 or 2028, and not on the list of the top 50 negotiation-eligible drugs for 2028 that CMS published with the third cycle. Linzess, selected in the second cycle, gets a negotiated price of $136 for 30 days from 1 January 2027; Trulance has no equivalent.
No generic, on the record
Drugs@FDA (data updated 13 November 2026) lists one plecanatide application: NDA 208745, Salix Pharmaceuticals, 3 mg tablet, approved 19 January 2017, prescription status. There is no generic (ANDA) approval. FDA's drug-listing directory, read the same day, holds Trulance as the only finished plecanatide product — packaged as 30-tablet bottles and 1-, 3- and 7-tablet sample cartons — and five listings of plecanatide as bulk ingredient, from Aurobindo, Chunghwa Chemical Synthesis & Biotech, MSN Life Sciences, Matrix Pharmacorp and AmbioPharm. Bulk ingredient is a raw material for manufacturing; its listing is not an approval to sell tablets.
The savings card
trulance.com, read 17 November 2026, states that eligible commercially insured patients "may pay as little as $25" per prescription fill for up to a 90-day supply, for up to 12 fills a year. The terms set a minimum out-of-pocket of $25 per prescription, a maximum savings limit that is not stated on the page, an age of 18 or over, and validity only in the US and Puerto Rico. They exclude anyone whose prescriptions are reimbursed in whole or part by a government programme — Medicare (including Medicare Advantage and Part D), Medicaid, TRICARE, the VA and others.
What these figures do not tell anyone
- A cash price at a given pharmacy. NADAC was an average acquisition cost and is now a year old for this drug; no cash-price site could be read.
- Net prices. Rebates to insurers are confidential; the Medicare figures are gross.
- A Medicaid enrollee's coverage today. The federal files show Trulance leaving the rebate file; a state plan decides what it covers.
- Whether Trulance is the right drug. The label sets one dose, 3 mg once daily, for both approved uses; the choice between drugs in this class belongs to the prescriber.
For how Trulance sits among the other approved peptide drugs, see our FDA-approved peptides census; prices across the peptide market are surveyed on how much do peptides cost. The same public files put one approved peptide drug far above Trulance: Medicaid paid about $1,484 a vial in 2024 for teduglutide, recorded on our page on what Gattex costs.
Sources
- Medicaid NADAC 2024, 2025 and 2026 datasets, data.medicaid.gov API, Trulance 3 mg (NDC 65649000330) and plecanatide, 2026 file as of 11 November 2026; read 17 November 2026.
- Drug Products in the Medicaid Drug Rebate Program, data.medicaid.gov (modified 9 November 2026), NDC 65649000330 and Linzess 290 mcg (00456120230), through 2026 Q3; read 17 November 2026.
- CMS, Medicare Part D Spending by Drug, 2020–2024 (data.cms.gov, modified 25 June 2026) and Medicare Quarterly Part D Spending by Drug, 2025 and 2026 Q1 (modified 23 July 2026), Trulance rows; read 17 November 2026.
- CMS, Selected Drugs and Negotiated Prices page; Fact Sheet: Selected Drug List for Initial Price Applicability Year 2028; Fact Sheet: Top 50 Negotiation-Eligible Drugs for 2028; read 17 November 2026.
- Drugs@FDA via openFDA (NDA 208745), data updated 13 November 2026; openFDA NDC directory, query
generic_name:plecanatide; Trulance prescribing information via openFDA labels (effective 4 April 2024); all read 17 November 2026. - trulance.com savings page and offer terms; bauschhealthpap.com home page; both read 17 November 2026.
- Refused (excluded): goodrx.com/trulance (redirected to a block page), singlecare.com (HTTP 403), drugs.com price guide (HTTP 403), all 17 November 2026.
